Asahi Kasei Licenses Novel Electrolyte Technology to EAS Batteries
Global manufacturer Asahi Kasei and German battery manufacturer EAS Batteries signed a license agreement for the use of Asahi Kasei's acetonitrile-containing electrolyte technology.
license agreement
Orion and Abzena Announce Exclusive Antibody Commercial License
Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, announced that Orion has obtained an exclusive focused commercial license to one of Abzena’s mAbs..
MSD Licenses Cardiovascular Drug from Hengrui Pharma
MSD (Merck & Co.) and Hengrui Pharma recently announced that they have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a) inhibitor.
AbbVie Teams up with Gubra to Develop Obesity Treatment
The US pharmaceutical giant AbbVie and Danish biotechnology company Gubra, specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, signed a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.
Newron Licenses Evenamide to Myung In Pharm
Newron Pharmaceuticals, a central nervous system (CNS) focused biopharmaceutical company, and Myung In Pharm, South Korea’s leading CNS pharmaceutical company, today announced that they have entered into a license agreement to develop, manufacture, and commercialize Newron’s schizophrenia treatment evenamide.
Innovent Licenses Lung Cancer Therapy Candidate to Roche
Chinese biopharmaceutical company Innovent Biologics announced a collaboration and exclusive license agreement with Roche to advance the development of IBI3009, a novel DLL3-targeted antibody-drug conjugate (ADC) candidate.
Merck & Co. Licenses Obesity Drug from Hansoh Pharma
US Merck & Co., operating as MSD outside the US and Canada, and Chinese biopharmaceutical company Hansoh Pharma have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. GLP-1 receptor agonists are primarily used for the treatment of type 2 diabetes and obesity.
Newron Licenses Schizophrenia Treatment to EA Pharma
Italian drugmaker Newron Pharmaceuticals and EA Pharma, a subsidiary of Japan’s Eisai, today have entered into a license agreement to develop, manufacture and commercialize Newron’s evenamide in Japan and other designated Asian territories.
Ascendis Licences Proprietary Technology to Novo Nordisk
Danish biopharma company Ascendis Pharma will grant pharmaceutical giant Novo Nordisk an exclusive worldwide license to its TransCon technology platform to develop, manufacture, and commercialize proprietary products for the treatment of metabolic and cardiovascular diseases.
Mestag Signs License and Research Deal with Merck & Co.
Mestag Therapeutics, a Cambridge, UK-headquartered biotech company working on new insights into fibroblast-immune interactions, has signed a license and collaboration agreement with US drugmaker Merck & Co., known as MSD outside of North America, to identify novel targets for the development of therapies against inflammatory diseases.
Carbios & Sasa Discuss Licensing PET Biorecycling Facility
Carbios, a company specializing in biological technologies for the life cycle of plastic and textiles, and Sasa, a manufacturer of polyester and related products, have signed a Letter of Intent (LOI) to explore the potential acquisition of a license for Carbios’ PET biorecycling technology by Sasa.
AstraZeneca Granted Global Starmap AI License for Nanoform
Nanoform, a nanoparticle medical technology company, has awarded AstraZeneca a global online STARMAP license. STARMAP is an AI-based digital rendition of CESS technology, facilitating in-silico experiments for selecting molecules to be nanoformed. This license enables AstraZeneca to screen molecules during the entire drug development process.
